Dr Reddy's Laboratories has succeeded in developing a copycat or generic version of Pfizer's Lipitor, the world's largest selling drug which has sales of over $10 billion.
The OTC major plans to pump in millions of dollars into Vedants' manufacturing facility coming up by 2011 at Ambernath near Mumbai. Perrigo will then move production of active pharmaceutical ingredients (APIs or the key therapeutic substance in a drug) from its sites in Germany and Israel to India.
Fresh power capacity addition has fallen short of target by nearly a third in the first half (April-September) of the current fiscal, owing to delays in the supply of critical components in thermal projects, delayed forest clearances and non-availability of fuel for a nuclear power project.
Nandini Piramal, heir apparent to the Piramal business empire as the elder child of Ajay Piramal and Swati Piramal, became the executive director of Piramal Healthcare in April this year. A 29-year-old graduate from Hertford College of Oxford University, with an MBA from the Stanford Graduate School of Business, she joined the firm in 2006 as a General Manager and has been closely associated with the company's overseas subsidiaries in the US and Canada.
India's ambitious plans to generate an additional 180,000 Mw of power in the next seven years will face hurdles if Indonesia, the second largest supplier of thermal coal, goes ahead with plans to cap coal exports to serve domestic demand.
Indian drug companies have cornered an overwhelming majority of drug approvals under the US President's Emergency Plan for AIDS Relief.
Teva Women's Health filed a suit this week in the US District Court for New Jersey, claiming that Lupin had filed an abbreviated new drug application with the US Food and Drug Administration, which infringes the patents of Seasonale, its oral contraceptive that limits the number of menstrual periods women have in a year.
Nova's new owner has decided not to pursue this project.
A German bankruptcy court has sold off Reliance Industries' polyester making subsidiary Trevira GmbH to two local entrepreneurs for an undisclosed amount.
Pricing worries remain, but bankers expect IPOs to raise over Rs 40,000 crore (Rs 400 billion) in the next few months.
Domestic drug major Cipla Ltd has signed a long-term collaboration agreement with Swiss specialty pharmaceutical major Meda, to develop and market an anti-allergic rhinitis drug for various global markets. Cipla will manufacture the drug, which will treat an ailment that causes a runny nose, and the Swiss company will market the product in Europe, Japan, Brazil, South Korea and Australia. The partners are developing the product as a nasal spray to treat allergic rhinitis.
Meeting will confine discussion to processes involved in building consensus among members.
PLSL's lead molecule under development for cancer treatment has completed two Phase-I studies.
JSW Energy aims to generate 11,390 Mw in the country by 2015. The company has tied up with two consortiums of lenders, led by IDBI Bank and State Bank of India, respectively, for the loans. It had recently filed a draft red-herring prospectus for a Rs 3,000 crore (Rs 30 billion) public offering with market regulator Securities and Exchange Board of India.
Mumbai-based Ajanta Pharma has tied up with the Canadian vaccine maker, Medicago Inc, to commercialise Medicago's pandemic and seasonal influenza vaccines in India and other territories.
The delay in the monsoon arrival had caused water storage to touch a historic low of 9 per cent in June (see table), as per data from the Central Water Commission. The latest data of Central Electricity Authority shows daily power availability in the country was 0.7 per cent ahead of demand on August 12 from an 8-10 per cent deficit last month.
GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
India will commission its first 500-Mw fast breeder reactor (FBR) for generating commercial nuclear energy by the end of next year. The reactor, when commissioned, will mark the country's entry into the second phase of its three-stage nuclear energy programme.
In a written reply to a question asked in Parliament earlier this week, minister of state for power Bharatsinh Solanki admitted that the coal stock position at some of NTPC's power stations had depleted. NTPC Ltd, the country's largest power generator, however, denies any shortage of dry fuel.
Two traders - Jindal Steel and Power Ltd and GMR Energy Ltd - have already surrendered their licences.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances